Matt Abernethy, Chief Financial Officer at NEUROCRINE BIOSCIENCES INC (NBIX), sold 900 shares at $150.04 ($135K) on 2024-07-16, disclosed to the SEC on 2024-07-18.
Scheduled sale ($135k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| NBIX | SELL | 2025-02-12 | $232K | — | Filing → |
| NBIX | SELL | 2025-02-04 | $392K | — | Filing → |
| NBIX | SELL | 2024-08-15 | $2.1M | — | Filing → |